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CT1
ESPAC-1 INTERIM RESULTS: A EUROPEAN, RANDOMISED
STUDY TO ASSESS THE ROLES OF ADJUVANT
CHEMOTHERAPY (5 FU+FOLINIC ACID) AND ADJUVANT
CHEMORADIATION (40 GY+5 FU) IN RESECTABLE PANCREATIC
CANCER JP Neoptolemos*1, JA Dunn2, DD Moffitt2, J Almond1, HG Beger3,
KH Link3, P Pederzoli4, C Bassi4, C Dervernis5, L Fernandez-Cruz6, F
Lacaine7, D Spooner8, DJ Kerr2, H Freiss9, MW Büchler9, 1Royal Liverpool
University Hospital, Daulby St, Liverpool L69 3GA, UK, 2CRC Institute for
Cancer Studies, Birmingham, UK, 3Ulm University Hospital of Surgery,
Germany, 4University of Verona, Italy, 5Agia Olga Hospital, Athens, Greece,
6Barcelona University Hospital, Spain, 7Hopital Tenon, Paris, France,
8Birmingham Oncology Centre, UK, 9University of Berne, Switzerland
Pancreatic cancer affects 8–12 per 100,000 population per year in Europe and North
America. Post-resection, long term survival is only 10–15% and the role of adjuvant
treatment is uncertain.
Previously GITSG randomised 43 patients showing increased survival in patients
receiving chemoradiation (40 Gy+5 FU) then weekly 5 FU compared to controls. The
Norwegian Pancreatic Cancer Trial Group randomised 47 patients showing increased
median survival in chemotherapy (FAM) patients compared to controls but no overall
survival difference. The EORTC trial of 114 patients did not show an advantage for
postoperative chemoradiation (40 Gy+5 FU) compared to controls but the UK
Pancreatic Cancer Group concluded that the GITSG regimen might enhance survival
in patients with negative lymph nodes.
ESPAC-1 is the largest randomised adjuvant pancreatic study aiming to answer
two questions: (i) is there a role for chemoradiation (40 Gy+5 FU); (ii) is there a role
for chemotherapy (weekly 5 FU/FA). So far, 530 patients with pancreatic ductal
adenocarcinoma have been randomised from 80 clinicians in 11 countries. Presently,
239 patients (45%) are alive with median follow-up of 9 (IQR 1–24) months.
Preliminary results show no evidence of a benefit for chemoradiation treatment
(median survival 14 months with chemoradiation vs 15.7 months without, p=0.24).
There is some evidence of a survival benefit for patients having chemotherapy
(median survival 19.5 months with chemotherapy vs 13.5 months without, p=0.003).
The effect is reduced when taking into account whether patients received radiotherapy
(p=0.01), indicating that radiotherapy may reduce the overall benefit of the
chemotherapy.
The Data Monitoring Committee (July 1999) recommended closing recruitment to
the radiotherapy question. The trial continues to randomise between chemotherapy
and observation to provide a reliable estimate of the difference between chemotherapy
and surgery alone. The trial will roll into ESPAC-3, due to open June 2000
randomising between: (i) Surgery alone, (ii) 5 FU/FA, (iii) Gemcitabine.
CT2
MEDICAL RESEARCH COUNCIL (MRC) RANDOMISED PHASE
III TRIAL OF SURGERY WITH OR WITHOUT PRE-OPERATIVE
CHEMOTHERAPY IN RESECTABLE CANCER OF THE OESOPHAGUS 
PI Clark,* On behalf of the MRC Upper GI Tract Cancer Group, MRC Clinical
Trials Unit, 222 Euston Road, London NW1 2DA, UK
Background The outlook for patients with oesophageal cancer undergoing surgical
resection with curative intent remains poor, with approximately 20% alive at 2 years.
There is increasing interest in the role of pre-operative chemotherapy.
Methods We conducted a randomised controlled trial (OE02) to assess the effects
of pre-operative chemotherapy on survival and physical wellbeing. We planned to
randomise 800 patients; this would enable an increase in 2-year survival from 20% to
30% to be detected with 5% significance level and 90% power.
Results Between March 1992 and June 1998, 802 previously untreated patients
with resectable oesophageal cancer of any cell type, and fit for resection and
chemotherapy, were randomised to either two 4-day cycles, 3 weeks apart, of cisplatin
80 mg/m2 by 4-hour infusion plus fluorouracil 1 g/m2/day by infusion for 4 days,
followed by surgical resection (CS group), or surgical resection alone (S group). In the
CS and S groups respectively, median age was 63 and 62 years; 77% and 74% were
male; 66% and 67% had adenocarcinoma, 64% and 63% had lower third tumours, and
WHO performance status was similar. Resection was considered complete in 84% CS
compared with 71% S patients; and 9% and 10% died within 30 days of resection.
Post-operative complications were similar (CS 38%, S 41%) and physical activity,
dysphagia, and general wellbeing improved similarly in the two groups following
treatment. In intent-to-treat analyses, overall survival was better in the CS group
(hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.64–0.91; p = 0.002). Median
survival was 17.4 months compared with 13.4 months (difference 4 months; 95% CI
1.3–7.6 months), and 2-year survival rates were 45% and 35% (difference 10%; 95%
CI 3%–16%). Progression-free survival was superior in the CS group (HR 0.71; 95%
CI 0.60–0.84; p < 0.001), and there was no evidence of a different treatment effect
according to histology.
Conclusion In conclusion, in the treatment of patients with resectable oesophageal
cancer, two cycles of pre-operative cisplatin and fluorouracil improved survival
without incurring additional serious adverse events.
CT3
QUASAR: A UKCCCR STUDY OF ADJUVANT
CHEMOTHERAPY (CT) FOR COLORECTAL CANCER DJ Kerr,
R Gray, C McConkey, J Barnwell, N Williams for the QUASAR group, CRC
Inst. for Cancer Studies, University of Birmingham, UK
QUASAR is a large simple pragmatic trial which aims to determine which colorectal
cancer patients should receive adjuvant chemotherapy (CT) and which CT to use.
Patients with a clear indication for CT, and without metastases or other evident
residual disease, were randomised in a 2´2 design to receive 5-fluorouracil (370
mg/m2) with either high (175 mg) or low dose (25 mg) L-folinic acid, and coupled
with either levamisole or placebo. The CT could be given, by clinician’s choice, either
as six-5-day courses at monthly intervals or as thirty once weekly doses. Patients for
whom there is substantial uncertainty whether or not they should receive CT are
randomised equally between CT and observation only with CT considered on recur-
rence.
The trial opened in May 1994 and has randomised 6409 patients from 145 centres
in the UK and elsewhere. The CT comparisons closed in October 1997 with 4927 and
4863 randomised into the folinic acid dose and levamisole comparisons, respectively.
The uncertain indication randomisation continues with 2100 patients randomised into
a target of 2500 patients. The randomised comparisons suggest that there are no
survival benefits from high-dose FA (p=0.43) or Levamisole (p=0.06 in favour of
placebo) (Lancet, in press); analysis based on 1576 deaths and 1776 recurrences.
Comparisons of the weekly and monthly schedules are also reported here. Although
this is a non-randomised comparison, the weekly and monthly groups are well
balanced with respect to prognostic variables. The weekly regime is much less toxic
and, apparently, about as effective as the monthly schedule. This suggests that toxicity
of FU/FA chemotherapy could be reduced substantially by weekly scheduling without
comprising efficacy. Alternatively, efficacy might be enhanced with equal toxicity by
more dose intense weekly FU regimens. But, this non-randomised comparison needs
confirming in randomised studies.
CT4
MITOXANTRONE IS SUPERIOR TO DOXORUBICIN IN A
MULTI-AGENT WEEKLY REGIMEN FOR PATIENTS WITH HIGH-
GRADE LYMPHOMA OVER THE AGE OF 60 YEARS: RESULTS OF A BNLI
RANDOMISED TRIAL OF PACEBO VS. PMITCEBO D Cunningham, PN
Mainwaring, W Gregory, P Hoskin, B Hancock, P Smith, G Vaughan Hudson,
D Linch, The British National Lymphoma Investigation at The CRC and UCL
Cancer Trials Office, London, UK
A prospective, multicentre, randomised trial was undertaken to compare the efficacy
and toxicity of adriamycin with mitoxantrone within a six drug combination
chemotherapy regimen for elderly patients (³ 60 years) with high-grade non-
Hodgkin’s lymphoma (HGL) given for a minimum of eight weeks. The adriamycin
containing regimen (PACEBO) consisted of prednisolone 50 mg p.o. days 1–14, adri-
amycin 35 mg/m2 IV day 1, cyclophosphamide 300 mg/m2 IV day 1, etoposide 150
mg/m2 IV day 1, bleomycin 10 mg/m2 IV day 8 and vincristine 1.4 mg/m2 day 8. In
the PMitCEBO arm the adriamycin was replaced by mitoxantrone 7 mg/m2 IV.
516 patients were entered into the trial and 473 patients were eligible for analysis.
The overall and complete response rates were 78% and 60% for patients receiving
PMitCEBO and 69% and 52% for patients receiving PAdriaCEBO, (P = 0.05, P =
0.12, respectively). Overall survival was significantly better with PMitCEBO
compared with PAdriaCEBO (P = 0.0067). There was a trend towards improved
lymphoma-specific survival in the PMitCEBO arm (P = 0.06), however, relapse-free
survival was not significantly different (P = 0.16). At 4 years, 28% PAdriaCEBO
patients and 50% of PMitCEBO patients were alive (P = 0.0001). Ann Arbor stage
III/IV, WHO performance status 2–4 and elevated LDH negatively influenced overall
survival from diagnosis. Significantly more patients died receiving PAdriaCEBO than
PMitCEBO (137 vs. 107, P = 0.04) with treatment-related deaths and toxicity not
significantly different between the two arms.
In view of these excellent results with PMitCEBO in elderly patients, a further
BNLI trial in this group of patients involves a 2´2 randomisation of PMitCEBO vs
CHOP with a second randomization to G-CSF or not. 412 patients have been entered
to date with a target accrual of 650 patients.
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CT5
PREOPERATIVE CONTINUOUS INFUSIONAL (EPIRUBICIN,
CISPLATIN AND INFUSIONAL 5 FU) V. CONVENTIONAL AC
CHEMOTHERAPY FOR EARLY BREAST CANCER: AS PHASE III
RANDOMISED TRIAL IE Smith, RP A’Hern, S Ebbs, A Howell, T Hickish, M
O’Brien, A Robinson, C Wilson, Royal Marsden Hospital, London: Mayday
Hospital, Croydon; Christie Hospital, Manchester; Royal Bournemouth
Hospital; Kent Cancer Centre; Southend Hospital; Addenbrooke’s Hospital,
Cambridge; UK on behalf of TOPIC Trial Group
Continuous infusional (ci) ECisF (E 60 mg/m2 iv bolus, Cis 60 mg/m2 iv, both ´ 3
weekly (wk) ´ 6 courses, with ci 5 FU 200 mg/m2 ´ 24 hourly ´ 18 wk by ambulatory
pump) is highly active preoperatively with an overall response rate of 98% and complete
remission 66% (J Clin Oncol 13: 424, 1995). We have therefore compared ci ECisF with
conventional AC (Adriamycin 60 mg/m2, Cyclophosphamide 600 mg/m2 both iv ´ 3w k
´ 6 courses) in a phase III multicentre randomised trial (TOPIC). 426 pts with needle
biopsy proven invasive operable ³3 cm breast cancer were randomised to receive either
ci ECisF (211 pts) or AC (215 pts), followed by appropriate local surgery ± radiotherapy
and tamoxifen 20 mg daily ´ 5 years. Patient characteristics for ci ECisF v. AC respec-
tively were as follows: median age 46 (range 22–68) v. 47 (range 25–66) yrs,
premenopausal 64% v. 66%, median tumour diameter 5 (range 3–11) v. 5 (3–15) cm.
Results at median follow-up of 30 months for ECisF v. AC respectively were as follows:
ci ECisF AC
Complete Remission 34% 31% p=0.53
Overall Response 77% 75% p=0.56
3-yr Mastectomy Rate 37% 43% p=0.13
3-yr Relapse Free Survival 77% 66% HR 0.77 (0.52–1.14) p=0.19
3-yr Overall Survival 90% 80% HR 0.56 (0.32–0.97) p=0.04
Grade 3/4 toxicity was low in both arms but significantly worse for ECisF for nausea
and vomiting (21% v. 10%), diarrhoea (7% v. 2%), thrombosis (17% v. 2%),
palmar/plantar erythema (14% v. 1%), and significantly better for alopecia (with scalp
cooling) (51% v. 74%). This interim analysis shows a significant survival benefit for
infusional 5 FU-containing chemotherapy over conventional AC, despite no signifi-
cant difference in clinical complete remission or overall response rates. Non-clinical
parameters (pathological or biological, which have run in parallel) may predict better
for survival.
CT6
ROLE OF RADIOTHERAPY AND DURATION OF TAMOXIFEN IN
EARLY BREAST CANCER (STAGE I): WEST MIDLANDS
BREAST GROUP PROSPECTIVE RANDOMISED COLLABORATIVE
STUDY (BR3002) D Spooner, JA Dunn, JM Morrison, GD Oates, DR  Ellis,
JR Lee. A Aukland, RJ Grieve, RJ Blunt, HM Bishop, L Dodson, On behalf of
the West Midlands Breast Group. CRC Trials Unit, Institute of Cancer
Studies, University of Birmingham B15 2TA, UK
Between August 1985 and December 1992, 707 patients with early breast cancer (less
than 4 cm diameter with clinically negative axillae) were treated with wide local exci-
sion only and then randomised to receive immediate post-operative radiotherapy to
the breast and axilla or observation only. All patients were further randomised to stop
Tamoxifen after 2 years or continue.
All patients now have a minimum of 5-year follow-up, median 8 years [IQR
6.4–9.7] years. The radiotherapy results show an expected excess of local relapses in
the no radiotherapy arm (c2=22.9, P<0.0001) which has a significant impact on breast
cancer specific survival (P=0.04) and a trend on overall survival (P=0.06). Looking at
the duration of Tamoxifen, there is no significant excess of recurrences (P=0.24) or
deaths (P=0.11) in either arm but again a trend in favour of continuous Tamoxifen.
These trends hold true when stratifying by prognostic factors. The compliance with
Tamoxifen allocation will also be presented.
This is a mature, important study looking at the impact of conservation treatment.
These results looking at the role of radiotherapy and duration of Tamoxifen enforce
those shown in the Oxford Overviews.
CT7
CHEMOTHERAPY IN HIGH-GRADE GLIOMA: A META-
ANALYSIS USING INDIVIDUAL PATIENT DATA FROM
RANDOMISED CLINICAL TRIALS (RCTS) LA Stewart, S Burdett1, RL
Souhami2, on behalf of the Glioma Meta-analysis Trialists Group, 1MRC
Clinical Trials Unit, London, UK, 2University College London Medical School,
London, UK
A prospectively defined systematic meta-analysis assessed the role of chemotherapy
in the treatment of adult patients with high-grade glioma. Individual patient data were
obtained from 10 RCTs comparing radiotherapy alone with radiotherapy plus
chemotherapy, mostly nitrosoureas either alone or in combination. The meta-analysis
included 2368 patients and 2106 deaths. Data were combined using the stratified (by
trial) log rank test to calculate pooled hazard ratios (HRs). Absolute differences were
calculated from each HR and the corresponding control group event rate at 2 years.
Endpoint HR Absolute Difference p-value
(95% CI) At 2 years
Survival 0.84 5% (from 15 to 20%) 0.0001
(0.77–0.92)
Recurrence-free 0.80 6% (from 10 to 16%) 0.00008
survival (0.72–0.90)
The results show a significant benefit of chemotherapy with a 16% relative reduc-
tion in the risk of death. This is equivalent to an absolute improvement of 5% at 2
years (95% confidence interval 3 to 9%) increasing the survival rate from 15% to
20%. There was no evidence that the effect of chemotherapy was different in any
group of patients defined by age, sex, histology, performance status or extent of resec-
tion. This small but clear improvement in survival from chemotherapy encourages
further study of systemic treatment of these tumours.
CT8
AUDIT OF CLINICAL TRIAL ELIGIBILITY AND RECRUITMENT
RATES IN A SINGLE SPECIALITY CANCER CENTRE 
TS Maughan*1,2, L Branston2, LA Batt1 and SH Shankland1,2, Clinical Trials
Unit, Velindre NHS Trust, Whitchurch, Cardiff CF14 2TL, 2Wales Cancer
Trials Network, Velindre NHS Trust, Whitchurch, Cardiff CF14 2TL, UK
This abstract reports a retrospective audit of cancer trial activity in a single speciality
cancer centre in South East Wales. The audit included all referrals to the hospital in
October 1998 and March 1999. The medical summary sheet for each patient referred
was reviewed by specialist oncology research nurses with a view to determining
whether the patient was potentially eligible for any of the 40+ open trials running in
the hospital at the time. Each summary sheet was coded according to the scheme
below and difficult cases were reviewed in audit meetings. The results are
summarised in the table below.
Oct 98 Mar 99 TOTAL
Assessable records 343 364 707
Not eligible/no trial available 238 289 527 (74.5% of referrals)
Potentially eligible 83 80 163 (23% of referrals)
Eligible but not approached 31 41 72 (44% of eligible)
Eligible & declined 33 24 57 (35% of eligible)
Eligible and in trial 19 15 34 (21% of eligible)
4.8% of all referrals
Over 70% of patients were ineligible for trial entry from the outset because of poor
performance status, stage of disease or no trial being available for certain cancers.
However, the audit helped highlight areas where interventions could be targeted to
increase recruitment of the remaining potentially eligible patients. These could include
educating medical personnel about the trial portfolio, giving training in informed
consent where refusal rates are high, screening notes and identifying possible trials
before the consultant sees the patient and support to satellite clinics where there were
patients who were not approached about trials.
A study by Spiro et al.1 at two centres with a major interest in lung cancer reported
that 11.7% of patients referred were randomised into the Big Lung Trial. Whilst the
authors judged this to be disappointing, it compares favourably with the 4.8% in this
audit. It would be useful to repeat audits of this kind in other settings to establish achiev-
able ranges for trial recruitment in UK cancer hospitals.
1 Spiro SG, Gower NH, Evans MT, Facchini FM, Rudd RM. Recruitment of
Patients with Lung cancer into a Randomised Clinical Trial: Experience at 2
Centres. Thorax (in press)